Clinical effect of postconditioning in ST-elevation myocardial infarction patients treated with primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials

作     者：Xian-qing HU Jian CHENG Biao TANG Zhong-heng ZHANG Ke HUANG Yi-ping YANG Yan-yan MAO Ming ZHONG Shen-wen FU 

作者机构：Department of Cardiovascular MedicineJinhua Municipal Central Hospital Department of Critical Care MedicineJinhua Municipal Central Hospital 

出 版 物：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》 (浙江大学学报（英文版）B辑（生物医学与生物技术）)

年 卷 期：2015年第16卷第3期

页      面：198-207页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：supported by the Science and Technology Research Program of Jinhua Municipality(No.2014-3-052) China 

主　　题：Myocardial infarction Postconditioning Coronary intervention 

摘      要：Objective： To evaluate the clinical effect of postconditioning on patients with ST-elevation myocardial infarction （STEMI） treated with primary percutaneous coronary intervention （PCI）. Methods： Randomized controlled trials were identified by searching relevant databases published up to April 2nd, 2014. A meta-analysis of eligible studies was performed by Stata 12.0 and Review Manager 5.2 with a fixed-effect model. Results： Ten studies providing adverse cardiac events in a total of 1346 STEMI patients treated with primary PCI were identified. The occurrence of heart failure was significantly reduced in patients treated with postconditioning compared with usual care （risk ratio （RR） 0.533; 95% confidence intervals （CI） 0.368-0.770）, whereas non-fatal reinfarction slightly increased in the postconditioning group （RR 2.746; 95% CI 1.007-7.488）. No significant difference in total major adverse cardiac events （MACEs） was observed between the two groups （RR 0.876; 95% CI 0.671-1.144）. Conclusions： Postcondi- tioning in STEMI patients undergoing primary PCI significantly reduces the risk of heart failure, but fails to decrease the incidence of total MACEs and the risk of non-fatal reinfarction.